Literature DB >> 18852138

Identification of small-molecule inhibitors of autotaxin that inhibit melanoma cell migration and invasion.

Lauren P Saunders1, Amy Ouellette, Russ Bandle, William Chozen Chang, Hongwen Zhou, Raj N Misra, Enrique M De La Cruz, Demetrios T Braddock.   

Abstract

Autotaxin (ATX) is a prometastatic enzyme initially isolated from the conditioned medium of human melanoma cells that stimulates a myriad of biological activities, including angiogenesis and the promotion of cell growth, survival, and differentiation through the production of lysophosphatidic acid (LPA). ATX increases the aggressiveness and invasiveness of transformed cells, and ATX levels directly correlate with tumor stage and grade in several human malignancies. To study the role of ATX in the pathogenesis of malignant melanoma, we developed antibodies and small-molecule inhibitors against recombinant human protein. Immunohistochemistry of paraffin-embedded human tissue shows that ATX levels are markedly increased in human primary and metastatic melanoma relative to benign nevi. Chemical screens identified several small-molecule inhibitors with binding constants ranging from nanomolar to low micromolar. Cell migration and invasion assays with melanoma cell lines show that ATX markedly stimulates melanoma cell migration and invasion, an effect suppressed by ATX inhibitors. The migratory phenotype can be rescued by the addition of the enzymatic product of ATX, LPA, confirming that the observed inhibition is linked to suppression of LPA production by ATX. Chemical analogues of the inhibitors show structure-activity relationships important for ATX inhibition and indicate pathways for their optimization. These studies suggest that ATX is an approachable molecular target for the rational design of chemotherapeutic agents directed against malignant melanoma.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18852138      PMCID: PMC7857123          DOI: 10.1158/1535-7163.MCT-08-0463

Source DB:  PubMed          Journal:  Mol Cancer Ther        ISSN: 1535-7163            Impact factor:   6.261


  45 in total

1.  A Simple Statistical Parameter for Use in Evaluation and Validation of High Throughput Screening Assays.

Authors: 
Journal:  J Biomol Screen       Date:  1999

Review 2.  Lysophosphatidic acid signaling: how a small lipid does big things.

Authors:  Celine Luquain; Vicki A Sciorra; Andrew J Morris
Journal:  Trends Biochem Sci       Date:  2003-07       Impact factor: 13.807

3.  Ascitic fluid from human ovarian cancer patients contains growth factors necessary for intraperitoneal growth of human ovarian adenocarcinoma cells.

Authors:  G B Mills; C May; M Hill; S Campbell; P Shaw; A Marks
Journal:  J Clin Invest       Date:  1990-09       Impact factor: 14.808

4.  Correction for light absorption in fluorescence studies of protein-ligand interactions.

Authors:  B Birdsall; R W King; M R Wheeler; C A Lewis; S R Goode; R B Dunlap; G C Roberts
Journal:  Anal Biochem       Date:  1983-07-15       Impact factor: 3.365

5.  An essential oligomannosidic glycan chain in the catalytic domain of autotaxin, a secreted lysophospholipase-D.

Authors:  Silvia Jansen; Nico Callewaert; Isabelle Dewerte; Maria Andries; Hugo Ceulemans; Mathieu Bollen
Journal:  J Biol Chem       Date:  2007-02-16       Impact factor: 5.157

6.  Site-directed mutations in the tumor-associated cytokine, autotaxin, eliminate nucleotide phosphodiesterase, lysophospholipase D, and motogenic activities.

Authors:  Eunjin Koh; Timothy Clair; Elisa C Woodhouse; Elliott Schiffmann; Lance Liotta; Mary Stracke
Journal:  Cancer Res       Date:  2003-05-01       Impact factor: 12.701

7.  Cloning, chromosomal localization, and tissue expression of autotaxin from human teratocarcinoma cells.

Authors:  H Y Lee; J Murata; T Clair; M H Polymeropoulos; R Torres; R E Manrow; L A Liotta; M L Stracke
Journal:  Biochem Biophys Res Commun       Date:  1996-01-26       Impact factor: 3.575

8.  Role for 18:1 lysophosphatidic acid as an autocrine mediator in prostate cancer cells.

Authors:  Yuhuan Xie; Terra C Gibbs; Yurii V Mukhin; Kathryn E Meier
Journal:  J Biol Chem       Date:  2002-06-25       Impact factor: 5.157

9.  Alpha-substituted phosphonate analogues of lysophosphatidic acid (LPA) selectively inhibit production and action of LPA.

Authors:  Guowei Jiang; Yong Xu; Yuko Fujiwara; Tamotsu Tsukahara; Ryoko Tsukahara; Joanna Gajewiak; Gabor Tigyi; Glenn D Prestwich
Journal:  ChemMedChem       Date:  2007-05       Impact factor: 3.466

10.  Characterization of human melanoma cell lines according to their migratory properties in vitro.

Authors:  Luis G Quiñones; Ivette Garcia-Castro
Journal:  In Vitro Cell Dev Biol Anim       Date:  2004 Jan-Feb       Impact factor: 2.416

View more
  36 in total

1.  A pharmacologic inhibitor of the protease Taspase1 effectively inhibits breast and brain tumor growth.

Authors:  David Y Chen; Yishan Lee; Brian A Van Tine; Adam C Searleman; Todd D Westergard; Han Liu; Ho-Chou Tu; Shugaku Takeda; Yiyu Dong; David R Piwnica-Worms; Kyoung J Oh; Stanley J Korsmeyer; Ann Hermone; Richard Gussio; Robert H Shoemaker; Emily H-Y Cheng; James J-D Hsieh
Journal:  Cancer Res       Date:  2011-12-13       Impact factor: 12.701

2.  Ligand-based autotaxin pharmacophore models reflect structure-based docking results.

Authors:  Catrina D Mize; Ashley M Abbott; Samantha B Gacasan; Abby L Parrill; Daniel L Baker
Journal:  J Mol Graph Model       Date:  2011-09-18       Impact factor: 2.518

Review 3.  G protein-coupled receptors: novel targets for drug discovery in cancer.

Authors:  Rosamaria Lappano; Marcello Maggiolini
Journal:  Nat Rev Drug Discov       Date:  2011-01       Impact factor: 84.694

Review 4.  Lysophosphatidic acid (LPA) receptors: signaling properties and disease relevance.

Authors:  Mu-En Lin; Deron R Herr; Jerold Chun
Journal:  Prostaglandins Other Lipid Mediat       Date:  2009-03-04       Impact factor: 3.072

5.  c-Jun promotes cell migration and drives expression of the motility factor ENPP2 in soft tissue sarcomas.

Authors:  Stefano Sioletic; Jeffrey Czaplinski; Lan Hu; Jonathan A Fletcher; Christopher D M Fletcher; Andrew J Wagner; Massimo Loda; George D Demetri; Ewa T Sicinska; Eric L Snyder
Journal:  J Pathol       Date:  2014-08-01       Impact factor: 7.996

6.  Autotaxin inhibitors: a perspective on initial medicinal chemistry efforts.

Authors:  Abby L Parrill; Daniel L Baker
Journal:  Expert Opin Ther Pat       Date:  2010-11-04       Impact factor: 6.674

7.  Inhibition of tumor growth and angiogenesis by a lysophosphatidic acid antagonist in an engineered three-dimensional lung cancer xenograft model.

Authors:  Xiaoyu Xu; Glenn D Prestwich
Journal:  Cancer       Date:  2010-04-01       Impact factor: 6.860

8.  Vinyl sulfone analogs of lysophosphatidylcholine irreversibly inhibit autotaxin and prevent angiogenesis in melanoma.

Authors:  Mandi M Murph; Guowei W Jiang; Molly K Altman; Wei Jia; Duy T Nguyen; Jada M Fambrough; William J Hardman; Ha T Nguyen; Sterling K Tran; Ali A Alshamrani; Damian Madan; Jianxing Zhang; Glenn D Prestwich
Journal:  Bioorg Med Chem       Date:  2015-07-02       Impact factor: 3.641

Review 9.  Taspase1: a 'misunderstood' protease with translational cancer relevance.

Authors:  D Wünsch; A Hahlbrock; S Jung; T Schirmeister; J van den Boom; O Schilling; S K Knauer; R H Stauber
Journal:  Oncogene       Date:  2015-12-14       Impact factor: 9.867

10.  Targeting melanoma growth and viability reveals dualistic functionality of the phosphonothionate analogue of carba cyclic phosphatidic acid.

Authors:  Molly K Altman; Vashisht Gopal; Wei Jia; Shuangxing Yu; Hassan Hall; Gordon B Mills; A Cary McGinnis; Michael G Bartlett; Guowei Jiang; Damian Madan; Glenn D Prestwich; Yong Xu; Michael A Davies; Mandi M Murph
Journal:  Mol Cancer       Date:  2010-06-09       Impact factor: 27.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.